One key failure mechanism is the logistic implementation for the DCT trials. A lot of times, when you go to a global trial, there's a lot of logistic management for DCT. Let's say you must ship the ...

There is a lot more guidance coming from FDA that recognizes that rare disease is a unique space for sponsors to design ...

While the AI story continues to unfold across the pharma industry, one aspect may be causing more issues than solutions. Dave Rusher, CCO at Aravo, joined Pharmaceutical Executive ...

Matt Turner, President of Patient Affordability, Paysign discusses the evolving financial threats to pharmaceutical ...

President of Patient Affordability, Paysign, mentions how Paysign's approach to measuring copay program value is in an effort to move beyond simple redemption counts toward a more complete picture of ...